DRUG AND THERAPY BULLETIN

Transcription

1 H.P. STATE COUNCIL DRUG AND THERAPY BULLETIN Issue: 13 Volume: 2 Oct 2018 Contents Message from the President Drug Updates Pharma News New Drug Approval Procedure in India Is it a bad idea to drink water after meals? Continuing Pharmacy Education Programme Local News Article by Meenakshi Verma Get all the information from Drug Information Center औष ध ज नक र क स सभ क र क स चन ए कर Toll Free DRUG INFORMATION CENTER HIMACHAL PRADESH STATE PHARMACY COUNCIL

2 DRUG AND THERAPY BULLETIN EDITORIAL Patron Mr. Gopal Krishan Sharma and Dr. Ran Singh Editor-in-chief Dr. Kamlesh Naik and Dr. M.S. Ashawat Co-Editors Dr. Vinay Pandit and Mr. Ankush Sharma Advisory Board Dr. Navneet Marwah, Mr. Sanjeev Pandit, Dr. Manoj Kumar, Dr. Ranjit Singh, Prof. CPS Verma, Dr. Poonam Sandhu, Dr. Rajender Guleria, Mr. Arvind Kumar, Mr. Bihari Lal Gupta, Mr, Hemant Sharma, Mr. Rakesh Chandel, Mr. Praveen Upadhya, Mr. Kamashwar Chauhan, Mr. Lokesh Kumar, Mr. Vishal Kumar, Mr. Y.S.Chandel, Mr. Birbal Sharma, Mr. Manoj Kumar, Mr. Yogesh Verma, Mr. Surender Nadda, Dr. Parshuram Content Message from the President Drug Updates Pharma News Other Articles New Drug Approval Procedure in India Is it a bad idea to drink water after meals? Continuing Pharmacy Education Programme Local News Pics of CPE Program Article by Meenakshi Verma

3 ø MESSAGE On the eve of World Pharmacists Day, I would like to congratulate all the pharmacists. Our pharmacists have played pivotal role in research, manufacturing, maintenance and dispensing of quality medicines to alleviate suffering, promote health and improve quality of life of patients in association with other healthcare professionals. I would like to congratulate all our pharmacists on World Pharmacists Day. On this day, we stand by the following: { Uniform R&P rules, Pay scale, Promotion to all the Hospital Pharmacist like doctors and nursing personals in India { Totally ban on e-pharmacy in India { Appointment of only Registered Pharmacist in the industries instead of other degree { Separate directorate of Pharmacy in Himachal Pradesh { M. Pharmacy (Pr) course should be started { Patient counseling center should be started in every Medical College and district Hospital During the past 2 years, we at Himachal Pradesh Pharmacy Council have tried to adopt digitalization. We hope to do provide most of registration, renewal and queries related to HPSPC registrations to our pharmacists through our dedicated website and the dedicated Facebook page. Some of our achievements have been: µ Digitalization of HPSPC services online new registrations, renewals, re-entry, addition of qualifications, CPE, migration, etc. µ Dedicated Facebook page µ Dedicated Drug information Center (DIC and tollfree number for all DIC related queries µ Drug and Therapy Bulletin (DTB) was started last year with a view to provide up to date drug information to our pharmacists. All the past 12 issues to DTB are available on the HPSPC website µ Continuing pharmacy education (CPE) program registrations are made online a fool proof system µ In next 1 2 months, the registered pharmacist can access all information right from the profile at µ In upcoming days, we plan to launch a mobile app and provide all HPSPC services through that. ø Sh. Gopal Krishan Sharma, President, HPSPC I extend my best wishes to all the pharmacists of Himachal Pradesh and the entire India and hope they would continue to serve the society. Sh. Gopal Krishan Sharma, President HPSPC, Shimla Drug Information Center Tollfree

4 DRUG AND THERAPY BULLETIN DRUG UPDATES Fycompa for Younger peds in partial onset seizures On October 1, 2018, the US FDA expanded the pediatric (ped) use of Fycompa (perampanel) oral tablets and suspension to include treatment of partial-onset seizures with or without secondarily generalized seizures in patients with epilepsy 4 years of age or older. Previously approved for this indication in pediatric patients 12 years of age or older, Fycompa gained approval for this younger pediatric population based on interim results from a Phase III clinical trial which demonstrated similar safety and efficacy between adult and pediatric patients. Fycompa is also approved as adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in patients with epilepsy 12 years of age or older. Prescribing information can be found at: fycompa.com/-/media/files/ Fycompa/ Fycompa_ Prescribing_Information.pdf. Kyprolis for once weekly Kd70 On October 1, 2018, the US FDA expanded the use of Kyprolis (carfilzomib) IV injection to include a onceweekly dosing option in combination with dexamethasone (once-weekly Kd70) for patients with relapsed or refractory multiple myeloma. This expanded indication was approved based on data from the ARROW clinical trial in which patients treated with carfilzomib administered once 2 weekly at 70 mg/m with dexamethasone experienced superior progression-free survival and overall response rates compared with those treated with carfilzomib 27 2 mg/m with dexamethasone (not FDA-approved). Prescribing information can be found at: com/united_states/kyprolis/kyprolis_pi.pdf. Arikayce for MAC lung Disease On September 28, 2018, the US FDA approved Arikayce (amikacin liposome) inhalation suspension indicated in adults who have limited or no alternative treatment options, for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen in patients who do not achieve negative sputum cultures after a minimum of 6 consecutive months of a multidrug background regimen therapy. Arikayce, which is the first drug to be approved under the Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD) pathway, was approved based on a clinical trial in which patients treated with amikacin liposome plus a background antibacterial regimen had a higher percentage of no MAC bacterial growth compared with those treated with the background antibacterial regimen alone. Prescribing information can be found at: accessdata.fda.gov/drugsatfda_docs/label/2018/ s000lbl.pdf. Libtayo for CSCC On September 28, 2018, the US FDA approved Libtayo (cemiplimab-rwlc) intravenous injection for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who are not candidates for curative surgery or curative radiation. Libtayo is the first treatment option for the advanced form of CSCC, the second most common skin cancer. Approval came after safety and efficacy was demonstrated in 2 clinical trials where 47.2% of patients treated with Libtayo had their tumors shrink or disappear. Prescribing information can be found at: accessdata.fda.gov/drugsatfda_docs/label/2018/ s000lbl.pdf. 4

5 Emgality for migraine preventive treatment On September 27, 2018 the US FDA approved Emgality TM (galcanezumab-gnlm) subcutaneous injection for the preventive treatment of migraines in adult patients. The efficacy and safety of Emgality was demonstrated in EVOLVE-1 and EVOLVE-2 clinical trials that included patients with episodic migraine and the REGAIN trial that included patients with chronic migraines. The prescribing information can be found at: s000lbl.pdf. Vizimpro for metastatic NSCLC On September 27, 2018, the US FDA approved Vizimpro (dacomitinib) oral tablets indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test. Vizimpro was granted application priority review and orphan drug designation by the FDA. Patients treated with Vizimpro demonstrated a significant improvement in progression-free survival compared with those treated with gefitinib in a clinical trial. Prescribing information can be found at: accessdata.fda.gov/drugsatfda_docs/label/2018/ s000lbl.pdf. Copiktra for CLL/SLL and FL On September 24, 2018, the US FDA approved Copiktra TM (duvelisib) oral capsules indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) after at least 2 prior therapies and for relapsed or refractory follicular lymphoma (FL) after at least 2 prior systemic therapies. Copiktra, the first dual inhibitor of phosphoinositide 3- kinase (PI3K),-delta and PI3K-gamma to gain FDA approval, carries a boxed warning for fatal and serious toxicities, infections, diarrhea or colitis, cutaneous reactions, and pneumonitis. Prescribing information can be found at: accessdata.fda.gov/drugsatfda_docs/label/2018/ s000lbl.pdf. FDA approves opioid analgesic REMS On September 18, 2018, the US FDA approved the final Opioid Analgesic Risk Evaluation and Mitigation Strategy (REMS) as part of its broader efforts to address the opioid crisis. For the first time, the Shared System REMS applies to immediate-release opioid analgesics and requires that training be made available to healthcare providers who are involved in the management of patients with pain. The previous REMS applied to extended-release and long-acting opioid analgesics only and required training for prescribers only. The Opioid Analgesic REMS document can be found at Opioid_Analgesic_2018_09_18_REMS_Document.pdf. Ajovy to prevent migraines On September 14, 2018, the US FDA approved Ajovy TM (fremanezumab-vfrm) subcutaneous injection for the preventive treatment of migraines in adult patients. Ajovy, the first anti-calcitonin gene-related peptide treatment to gain FDA approval for migraine prevention, provides quarterly and monthly dosing options. In clinical trials, patients treated with fremanezumab-vfrm alone or in combination with oral preventive treatment experienced a decrease in monthly migraine days over a 12-week treatment period. 5

6 DRUG AND THERAPY BULLETIN Prescribing information can be found at: accessdata.fda.gov/drugsatfda_docs/label/2018/ s000lbl.pdf. Xelpros emulsion for IOP On September 14, 2018, the US FDA approved Xelpros TM (latanoprost) ophthalmic emulsion indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. Xelpros, which is the first benzalkonium chloride-free and emulsion formulation of latanoprost to gain FDA approval, was approved based on clinical trials in which treatment with latanoprost demonstrated a reduced IOP from baseline. Prescribing information can be found at: myxelpros.com/pdf/xelprospi.pdf. SubQ Actemra Now for SJIA On September 13, 2018, the US FDA approved the subq formulation of Actemra (tocilizumab) injection to include the treatment of active systemic juvenile idiopathic arthritis (SJIA) in patients 2 years of age and older. Actemra may be administered as monotherapy or combination therapy with methotrexate for SJIA. Efficacy was established based on pharmacokinetics exposure and extrapolation of established data for Actemra IV use in patients with SJIA as well as Actemra subq use in patients with rheumatoid arthritis. Full prescribing information can be found at: accessdata.fda.gov/drugsatfda_docs/label/2018/ s122,125472s031lbl.pdf. Lumoxiti for hairy cell leukemia On September 13, 2018, the US FDA approved Lumoxiti TM (moxetumomab pasudotox-tdfk) IV injection indicated to treat adult patients with relapsed or refractory hairy cell leukemia (HCL) who received at least 2 prior systemic therapies, including treatment with a purine nucleoside analog. The first of this type of treatment for patients with HCL, Lumoxiti was granted fast track, priority review, and orphan drug designations by the FDA. This new approval carries a boxed warning regarding the risk of developing capillary leak syndrome. Prescribing information can be found at: accessdata.fda.gov/drugsatfda_docs/label/2018/ s000lbl.pdf. Tiglutik oral suspension for ALS On September 6, 2018, the US FDA approved Tiglutik TM (riluzole) oral suspension indicated for the treatment of amyotrophic lateral sclerosis (ALS). The first oral suspension formulation to gain FDA approval, Tiglutik was approved based on clinical trials in which the bioavailability of riluzole oral tablets was compared with that of Tiglutik oral suspension. Prescribing information can be found at: accessdata.fda.gov/drugsatfda_docs/label/2018/ s000lbl.pdf. Reference: 6

7 PHARMA NEWS HC seeks Centre's reply on plea to take action against online pharmacies The Delhi High Court sought response of the Centre on a plea seeking direction to authorities to close down "illegal" online pharmacies, which are offering drugs and prescription medicines on their websites. The petition came up for hearing before Justice Vibhu Bakhru which listed it for further proceedings on February 25 next year. The court also sought replies of the Delhi government, Central Drugs Standard Control Organization, Drug Control Department. The plea by South Chemists and Distributors Association alleged that the online pharmacy stores were operating without any regulatory restrictions, in contrast to the rules which govern the sale of drugs and prescription medicines through offline pharmacies, also known as brick and mortar shops. Advocate Amit Gupta, appearing for the association, sought direction to the authorities to take immediate steps in closing down the online pharmacies operating within India in violation of the Drugs and Cosmetics Act, the Pharmacy Act and the relevant rules and regulations. Ref: NITI Aayog, Oracle, Apollo Hospitals, Strides Pharma team up for real drug supply NITI Aayog, India's think tank, has partnered with Oracle, Apollo Hospitals and drug maker Strides Pharma Sciences to work on a real drug supply chain using blockchain technology in a move to curb fake medicines. In a joint press release, NITI Aayog and the companies said they would pilot a real drug supply chain using block chain decentralized ledger and internet of things (IoT). According to the release, Oracle's block chain software permanently registers a drug's record in the manufacturer's drug supply chain (serial number, labeling, scanning), leaving no scope for record tampering. From here on, at every point of hand change, it records the drug's movement from manufacturer to logistics, from stockiest to hospital, or from pharmacy to consumer. In case of a fake drug, the software will detect irregularity and notify the concerned nodal point. Besides, Oracle IoT will provide options to track critical information such as chemical ingredients of the drug or maintenance of temperature control in case of life saving drugs or vaccines. The Indian government's think tank elaborated on the state of counterfeit drugs in India citing a recent report by World Health Organization that estimates 20% of all drugs sold in India are fake. The report also mentioned that India, largest producer of generic drugs in the world, is reported to be the source of 35% of all counterfeit drugs sold worldwide. Ref: Govt. relaxes import norms for certain chemicals used in pharma sector The government relaxed import norms for about 34 chemicals used in pharmaceuticals industry, a move which would ease inbound shipments of these items. The import rpolicy of 34 items "has been revised from restricted to fee subject to no objection certificate from Narcotics Commissioner, Gwalior, before import of the item", the directorate general of foreign trade (DGFT) said in a notification. The chemicals include cocaine, nor-ephedrine, cathine and its salts, ephedrine hydrochloride and concentrates of poppy straw, nicotinic acid and aminorex. Ref: 7

8 DRUG AND THERAPY BULLETIN Good Distribution Practices for pharmaceutical products coming soon At present transportation of drugs are carried out by third parties like contractors and sub-contractors in most cases. With a view to streamline and ensure the quality of drugs during transportation, the government is planning to bring in legislations and penalize the offenders. As part of this, the Drugs Controller General India (DCGI) has come out with draft guidelines on 'Good Distribution Practices' (GDP) for pharmaceutical products. At present the Rules 64 and 65 of the rule book vaguely suggest the conditions to be fulfilled to sell, stock, exhibit or distribute drugs. At present transportation of drugs are carried out by third parties like contractors and subcontractors in most cases. Contamination, cross contamination, mix-ups, adulteration and presence of spurious drugs are an issue in the unregulated distribution chain. Involvement of unauthorized entities in the distribution chain is also a concern. The guidelines are to ensure the quality and identity of pharmaceutical products during all aspects of the distribution process. These include procurement, purchasing, storage distribution, transportation, documentation and record keeping practices in the chain from the manufacturing plant to the medical stores. The draft guidelines suggest there will be collaboration and an agreement in place with all the agencies involved in the storage, distribution and transportation. The distributor and the organization he belongs to shall be held responsible for the activities that it performs related to the distribution of products. Export and import of pharmaceutical products will require appropriate licenses and drug distributors and subcontractors will require authorization. Besides training the people in the distribution chain as per predefined standard operating procedures (SOP), managements will have to ensure safety standards for people and property, environment and product integrity. Protective garments have to be given to people handling hazardous materials. The guidelines will mandate a documented quality policy, detailing intentions and requirements of distributors regarding quality, authorized by the management. Procedures will be in place to ensure documentation so that the products are traceable in the supply chain and help in monitoring product recall. Ref: Cabinet approves Agreement between India and Uzbekistan on cooperation in health and medical science The Union Cabinet chaired by Prime Minister Shri Narendra Modi has approved the signing of an Agreement between India and Uzbekistan on cooperation in health and medical science. The agreement expanding opportunities for the development of business cooperation in the field of medical equipments, including equipments for teaching and research laboratories of institutions of medical education, and pharmaceutical products. It will Strengthening of primary health care and setting up of health care facilities and Medical and health research development, as well as exchange of experience in these areas; The agreement also Exchange experiences and technologies in the field of telemedicine and electronichealth information systems. The agreement will also cover Maternal and child health protection. It will develop and improve techniques and strategies for epidemiological surveillance and communicable and non-communicable diseases control. The agreement also includes regulation of drugs and pharmaceutical products and any other areas of cooperation of mutual interest. Ref: 8

9 Constitution of Central Expert Committee and state level committee to determine the quantum of compensation in respect of faulty ASR hip implants Ministry of health and family welfare, Govt. of India had constituted a high power expert committee to examine issues related to the faulty ASR hip implants manufactured by M/s DePay International limited UK (now M/s Johnsons and Johnsons Pvt Ltd.) and imported by M/s DePuy Medical Pvt. Ltd. Mumbai (now M/s Johnson and Johnson Pvt Ltd.). The committee has submitted the report to ministry. The recommendation of the committee had been accepted with the certain modification by the ministry of health and family welfare, Govt. of India. The Govt. has also requested the Principal/health secretaries of all the states/uts to constitute the state level committees to examine the affected patient details in their respected states. The affected patients who are implanted faulty SR hip implants and are suffering from disability and other losses may approach either central expert committee or state level committee as per their convenience. In case the affected patients intend to approach central expert committee, they may write/mail to legal cell CDSCO (HQ), FDA Bhawan Kotla Road, New Delhi Phone No , Ext 315, ID: legalcell@cdsco.nic.in In case affected patients intend to approach State Level Committee, they may write to concerned state drug controller who will be member secretary of State Level Committee. Ref: Health Ministry issues a notification for bringing the HIV/AIDS Act, 2017 in force The Ministry of Health and Family Welfare has issued a notification for bringing the Human Immunodeficiency Virus and Acquired Immune Deficiency Syndrome (Prevention and Control) Act, 2017 in force from 10th September, Ref: Health ministry decide for renaming drug regulator CDSCO The Union Health Ministry decided for renaming the country's drug regulator CDSCO in line with its expanded roles. In a public notice issued on , the Central Drugs Standard Control Organization (CDSCO) said its name was given keeping its role when it was created, but the present nomenclature was not reflecting its roles and responsibilities. The notice said the role of CDSCO has expanded to several areas, including regulation of new drugs, vaccines and clinical trials, all imports pertaining to drugs, medical devices and cosmetics, Central Licensing Approval Authority for blood banks and vaccines, setting of standards under the Drugs and Cosmetics Act, 1940, laying down regulatory measures and proposing amendments of Acts and Rules, Emerging area such as stem cell, e-pharmacy etc. Dr R A Mashelkar in his report recommended creation of National Drug Authority (NDA) or Central Drug Authority (CDA). Ref: Government banned 328 FDCs in the country The Ministry of Health and Family Welfare has prohibited the manufacture for sale, sale or distribution for human use of 328 Fixed Dose Combinations (FDCs) with immediate effect. It has also restricted the manufacture, sale or distribution of six FDCs subject to certain conditions. In compliance with the directions given by the Supreme Court of India in its judgment dated the 15th December, 2017, the matter was examined by the 9

10 DRUG AND THERAPY BULLETIN Drugs Technical Advisory Board constituted under section 5 of the Drugs and Cosmetics Act, 1940 which furnished its report on these drugs to the Central Government. The Drugs Technical Advisory Board recommended, amongst other things, that there is no therapeutic justification for the ingredients contained in 328 FDCs and that these FDCs may involve risk to human beings. The Board recommended that it is necessary to prohibit the manufacture, sale or distribution of these FDCs under section 26 A of the Drugs and Cosmetics Act, 1940 in the larger public interest. Ref: 10

11 OTHER ARTICLES New Drug Approval Procedure in India The new drug approval is of two phase process the first phase for clinical trials and second phase for marketing authorization of drug. Firstly, non-clinical studies of a drug are completed to ensure efficacy and safety, and then application for conduct of clinical trials is submitted to the competent authority of the concerned country. Thereafter, the clinical trials can be conducted (phase I to phase IV). These studies are performed to ensure the efficacy, safety and optimizing the dose of drug in human beings. After the completion of clinical studies of the drug, then an application to the competent authority of the concerned country for the approval of drug for marketing is submitted. The competent authority review the application and approve the drug for marketing only if the drug is found to be safe and effective in human being or the drug have more desirable effect as compare to the adverse effect. Even after the approval of new drug, government should monitor its safety due to appearance of some side effects, when it is used in larger population. The interactions with other drugs, which were not assessed in a pre-marketing research trial and its adverse effects (in particular population) should also be monitored. Ref: Is it a bad idea to drink water after meals? Most of you might have heard that drinking water in between or after meals can affect your digestion. It can also prevent your body from absorbing nutrients properly and further lead to bloating. Well, there s some good news. All these claims about the bad effects of water on your body are not completely true. Hydration is not only good for our health, but it is also known to encourage digestion whether we drink water before or after meals Dr. Priyanka Rohatgi, chief nutritionist, Apollo Hospitals, says, Drinking water before, in between or after the meal is not a bad idea. If you have over eaten and are trying to drink small quantities of water, that can be a challenge. That increases your gastritis and you will have the food passing undigested and unabsorbed. Rohtagi further says drinking chilled water should be avoided after a heavy lunch or dinner, If you are drinking chilled water or chilled beverages, it will delay your digestion. Even after a heavy meal, you can have a glass of some warm or room temperature fluid but not excess quantity of water. If you have too much water, you will feel bloated and will have a quick and easy transit, which is not ideal. Limit the amount of water you drink. Just one or half a glass of water is good enough. Ref: 11

12 DRUG AND THERAPY BULLETIN Continuing Pharmacy Education Program HP State Pharmacy council (HPSPC) organized 'Continuing Pharmacy Education Program' as well as celebrated the 'Pharmacy Day' on 25th September, 2018 at SFDA Hall, Nahan, Distt. Sirmour. Pharmacy Day theme for year 2018 was 'Drug Free Hmara Pyara Himachal'. The registered pharmacists of Distt. Solan and Sirmour attended the above program on 25th September, The mentors of CPE program were Dr. Sachin Goyal (Principal, Himalyan Institute of Pharmacy Kala- Amb), Mrs. Sonia Arora (Associate Professor, Choudhary Din Dayal Institute of Pharmacy), Mr. Gaurav Sharma (Industrial Pharmacist). In the program, HPSPC also honored the senior pharmacists of Distt. Sirmour and Solan. Names of honored pharmacists are as follows: Sr. No. Name Reg. No. Date of birth From 1 Krishan Datt Sharma /01/1936 Nahan 2 Prem Chand Sharma /05/1939 Ponta Sahib 3 Kamal Lal /04/1946 Ponta Sahib 4 Pratap Singh Tomar /07/1946 Shilai 5 Mittar Singh Tomar /08/1954 Renuka Ji 6 Ruldu Ram Sharma /04/1946 Shilai 7 Gita Ram Sharma /04/1956 Rajgarh 8 Nek Ram /09/1958 Nahan u u Students of Himalayan Institute of Pharmacy Kala-Amb also performed cultural activity. During all the program stage was conducted by Mr. Surinder Nadda (Vice-Chairman DIC). 12

13 Media Coverage Ref: Amar Ujala, Ref: Divya Himachal, Ref: Amar Ujala,

14 DRUG AND THERAPY BULLETIN Pics of CPE Program 14

15 एक म क फ़ एक म क भ बन ए ज अपन कश रवय ब क ब र म हर ब फ म द रहत ह क कह व नश क च ग ल म न फ स ज य य द म र भ वन ओ क समझ कर एक भ कश र ख द क नश स दर रखन क ण ल त ह त म यह समझ ग क नश म हम चल बन न म म र यह अ त छ ट स य स सफल रह एक म क फ़ र त क त गहर न द म स त दख कर त र म थ च मन, त र जब टट लन, हथ लओ क सघ न, त र बग तल शन और बत रत ब पड़ त र क पय क प पलटत ज न, त म समझत ह यह शक ह, नह, यह शक नह फ़ ह त र व नत नए द बन न और उ घर ल कर आन, म र व उनस उनक प रव र क ब र म प छत ज न, त र स थ स थ त र उन द क म र हद यत दन, समझ न, और त र म र इन ब त स झ झल न, त म समझत ह यह शक ह, नह, यह शक नह फ़ ह दर र त क फ न क घ ट क घनघन न, और म र कस अनह न क आश क स सहम ज न, और फर त क पत उ ग लय स फ न लग न, कवरज स ब हर ह आव ज आन पर म र और भ घबर ज न, त म समझत ह यह शक ह, नह, यह शक नह फ़ ह कह त क ई नश क गत म न धक ल द, म र हर पल यह ख फ ख न, यह कभ पहल और आ खर ब र नह ह त, हर पल त यह समझ न, छन भर स ह जल दन व ल इस आग म कभ न अपन ह थ जल न, हर ब र यह द हर त ए त ह ल भ जन और त र प चन स भ पहल त फ न लग न त म समझत ह यह शक ह, नह, यह शक नह फ़ ह हम र सपन क प र करन क लए ब शक त म न र त क न द गव न, ख लन क दन छ ड़ कर, हर पल न कत ब म ख द क खप न द स ग घ मन और जदग क ल क अनम ल बन न बस यह ग ज रश ह नश क म य ज ल स ख द क बच न ओ म र दआओ म म ग, ओ म र म त क ध ग, इन जहर ल प ज स ख द क ट टन स बच न अब त म ह बत ओ यह शक ह, नह, यह शक नह फ़ ह म न वम स न फ म स ड व ई. एस. परम र म डकल क ल ज, न हन, जल सरम र ( ह..) 15

16 DRUG AND THERAPY BULLETIN Which kind of queries can be asked from Drug Information Center? It is the matter of pride for all the population of Himachal Pradesh that there is drug information center (DIC) in the state which is giving the services to promote the rational drug use. Maximum population of state knows that there is DIC, but they are unaware about the services of the DIC. They all are confused that which kind of queries they can ask. There is no any restriction to take the drug query information by any one. Any person (physician, pharmacist, nurse, patient, people of community, old persons, students, researchers etc.) can come in or call in the DIC office to take drug information. Following kinds of queries regarding drugs can be asked from DIC: Ÿ Ÿ Ÿ Ÿ Ÿ Ÿ If patient is administering two medicines at the same time then he/she before administering the medicine, can confirm from DIC that this combination is safe or not safe. If combination will be not safe then it may also be life threatening. If patient is administering a medicine then he/she can confirm which kinds of foods have to be avoided. Someone can confirm that use of any specific medicine in particular condition (like as pregnancy/lactation) is safe or not safe. General information about drug identification can also be taken from the DIC, like as use and side/adverse effects, time of administration, duration of administration, dose in different age groups etc. about any drug. Information about substituted drugs with different prices can also be provided by DIC. Any updation about medicines can be confirmed from DIC. DIC will provide the accurate information on request without any fear and favor. In short, we can say that DIC can provide any kind of information about any medicine to anyone without any cost. Personnel can assess directly, can call in the DIC office, sent the query by post, by 16

17 Personnel can assess directly, can call in the DIC office, sent the query by post, by on following address. आप अपन सव ल प छन क लए न च दए गए पत पर आ सकत ह आप अपन सव ल फ़ न, इ-म ल य ड क स भ प छ सकत ह Toll Free Note: If any want to publish his/her article in the monthly bulletin of Drug Information Center regarding Pharma updates, they can send their articles with their full address and professional status on the following reference before 25th of every month. न ट: अगर आप अपन क ई आ टकल इस ग इनफ मशन स ल ख हर मह न क २५ त र ख स पहल भ ज र र प क शत करव न च हत ह त हम आप अपन DRUG INFORMATION CENTER HIMACHAL PRADESH STATE PHARMACY COUNCIL Laureate Institute of Pharmacy, Kathog, Jwala Ji, Distt. Kangra HP Website: Mail ID: Toll Free , Phone: , Scan this Quick Response (QR) code to know read online You may download any QR code scanner from Play Store/iTunes 2018, Pharma Pulse